What does the Chinese military want with your unborn baby’s genetic data?
By Arwa Mahdawi,
The Guardian
| 07. 10. 2021
The BGI group has used data from its popular prenatal test to help the People’s Liberation Army improve ‘population quality’ but they are far from the only ones normalizing eugenics
Your unborn baby is already being monetized
Could data harvested from millions of pregnant women pave the way for genetically enhanced super-soldiers? According to a recent Reuters investigation, BGI Group, the manufacturers of a popular prenatal test, is working with the Chinese military towards that very goal.
BGI group offers a test called Nifty (“Non-Invasive Fetal TrisomY”), which is offered in more than 50 countries and is used to look for genetic abnormalities such as Down’s syndrome early on in a pregnancy. According to Reuters, more than 8 million women have taken these tests, and BGI has used the genetic data it has collected to help the Chinese military improve “population quality”. Reuters reports that US government advisers have warned that access to this massive databank could “propel China to dominate global pharmaceuticals, and also potentially lead to genetically enhanced soldiers, or engineered pathogens to target the US population or food supply”. BGI has issued a statement rejecting these claims.
“China is stealing your intimate data for evil purposes” is a popular genre in western journalism – see, for...
Related Articles
By Emma McDonald Kennedy
| 10.29.2026
At the beginning of Nathan Fielder and Lance Oppenheim’s blockbuster documentary You Can See Everything, Billy Evans (partner of Theranos founder and convicted fraudster Elizabeth Holmes), says that they decided to do the film for one purpose: “radical transparency.” As they work on “Theranos 2.0,” Evans and Holmes want to show the public that she has been misunderstood –– painted as a liar and a fraud in the public imagination (and the courts) despite, as she claims in the...
By Jonquilyn Hill, Vox | 10.18.2026
By Roxanne Khamsi, The Atlantic | 10.16.2026
In recent months, news came out about several distressing cases that have underscored the risks of gene therapy, which delivers DNA to a patient’s cells to treat disease. All of these cases have one thing in common that’s not apparent...
By Rebecca Roberts, The Scientist | 10.11.2026
Heritable genome editing in human embryos is once again under intense scrutiny after the publication of an opinion piece in Trends in Genetics at the end of last month.1 In the paper, Cathy Tie, the founder and chief...